Viewing nowCombinationTelmisartan/Rosuvastatin 80/10 mg
Telmisartan 80mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Hana Pharmaceutical Co., Ltd.

MFDS item code 201907250 · Approved 2019.10.15 · Insurance code 657806770
Treatment of essential hypertension and dyslipidemia; inhibition of atherosclerosis progression and cardiovascular disease risk
This medication is used in patients who require the combined administration of two drugs, telmisartan and rosuvastatin. Telmisartan is effective for the treatment of essential hypertension and helps to reduce the risk of myocardial infarction, stroke, and mortality due to cardiovascular disease in patients aged 55 and older with a high risk of cardiovascular disease. Rosuvastatin is used to lower blood cholesterol levels in patients with hypercholesterolemia and mixed hyperlipidemia, and to delay the progression of atherosclerosis. In addition, it contributes to reducing the risk of cardiovascular disease and the risks associated with stroke, myocardial infarction, and revascularization procedures in high-risk patients over a certain age. This medication effectively manages both hypertension and hyperlipidemia and significantly improves cardiovascular health.
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan/rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This medicine has an additional blood pressure-lowering effect when coadministered with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after treatment is started. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The effect of doses below 80 mg on reducing the risk of cardiovascular morbidity and mortality is unknown. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient to control the condition in most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Ethnicity: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience.
This medication may cause serious damage to the fetus, especially during pregnancy, so it should be discontinued immediately if pregnancy is confirmed. Patients with allergies to this medication or its components, pregnant women or those who may become pregnant, and breastfeeding mothers should not take this medication. Patients with severely impaired liver function or problems with bile excretion should not take this medication, and patients with abnormally high liver enzyme levels should also be cautious. Patients with muscle diseases or previous muscle-related side effects, as well as those with severe renal impairment, are prohibited from taking this medication. Elderly patients, those with elevated potassium levels, and those with mild liver dysfunction should use this medication cautiously and undergo regular liver enzyme and muscle-related tests. This medication may cause muscle-related side effects such as myalgia, muscle weakness, and muscle cramps, so if these symptoms occur, immediate consultation with a physician is required. Various side effects, including liver dysfunction, allergic reactions, hypotension, dizziness, and gastrointestinal disorders, have been reported, so if any unusual symptoms appear during use, patients should inform their healthcare provider immediately. This medication may interact with other antihypertensive agents or lipid-lowering medications, so patients taking other medications must inform their physician or pharmacist. Pregnant or breastfeeding women should not take this medication, and those planning on becoming pregnant should use appropriate contraception. It is not recommended for children as safety and efficacy have not been established. In cases of overdose, symptoms such as hypotension, dizziness, and acute kidney failure may occur, necessitating immediate medical attention. While taking this medication, patients should be cautious when driving or operating dangerous machinery as dizziness or drowsiness may occur.
Headache, positional dizziness, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, elevated ALT, dysuria, rhinitis, pharyngeal discomfort, lung disease, unspecified gastrointestinal disorder, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reactions, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, indigestion, abdominal distension, vomiting, abdominal discomfort, dry mouth, liver function abnormalities, liver disorders, increased sweating, itching, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, low back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, elevated liver enzymes, increased serum CK, decreased hemoglobin, angioedema, intravascular volume depletion, shock, loss of consciousness, jaundice, symptoms resembling anaphylaxis, interstitial pneumonia, rhabdomyolysis, palpitations, fatigue, nausea, lack of efficacy, facial spasms, sensory disturbances, paralysis, cough, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, edema, decreased libido, facial edema, alopecia, conjunctivitis, auditory hallucinations, petechiae, hypersensitivity reactions including angioedema, diabetes, constipation, pancreatitis, pruritus, myopathy, weakness, polyneuropathy, amnesia, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, interstitial lung disease, fatal and non-fatal liver failure, cognitive impairment, severe myasthenia gravis, ocular myasthenia gravis, headache, dizziness, elevated ALT, chest pain, myalgia, elevated CK, constipation, elevated AST, weakness, joint pain, fatigue, numbness, sensory disturbances, chest discomfort, nausea, abdominal pain, diarrhea, loss of appetite, abdominal distension, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, arrhythmia
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. It is important to maintain a storage temperature between 1 and 30 degrees Celsius. This will help to preserve the efficacy and safety of the medication.
Bright blue oval film-coated tablet
30 tablets/box [10 tablets/PTP*3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationTelmisartan 80mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Hana Pharmaceutical Co., Ltd.
CombinationTelmisartan 80mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhannanghang Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhan Corporation Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.